ProfileGDS5678 / 1456086_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 87% 84% 88% 84% 81% 84% 84% 85% 83% 84% 86% 84% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5695487
GSM967853U87-EV human glioblastoma xenograft - Control 26.7052787
GSM967854U87-EV human glioblastoma xenograft - Control 36.2786684
GSM967855U87-EV human glioblastoma xenograft - Control 46.9595888
GSM967856U87-EV human glioblastoma xenograft - Control 56.3238584
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5979581
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0596884
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1795384
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3123185
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0549983
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2611484
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.612886
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2383284
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0378883